Exploring mechanisms of increased cardiovascular disease risk with antipsychotic medications: Risperidone alters the cardiac proteomic signature in mice

Atypical antipsychotic (AA) medications including risperidone (RIS) and olanzapine (OLAN) are FDA approved for the treatment of psychiatric disorders including schizophrenia, bipolar disorder and depression. Clinical side effects of AA medications include obesity, insulin resistance, dyslipidemia, h...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Pharmacol Res
Hlavní autoři: Beauchemin, Megan, Geguchadze, Ramaz, Guntur, Anyonya R., Nevola, Kathleen, Le, Phuong T., Barlow, Deborah, Rue, Megan, Vary, Calvin P.H., Lary, Christine W., Motyl, Katherine J., Houseknecht, Karen L.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2019
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7060507/
https://ncbi.nlm.nih.gov/pubmed/31874253
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.phrs.2019.104589
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky